Ashok Krishnaswami1, Mary-Lou Kiley2, Faith F Anthony3, Yuexin Chen4, Jason Chen5, Sumanth Rajagopal6, Taylor I Liu7, Charlie Young8, Elizabeth W Paxton9. 1. Cardiologist at the San Jose Medical Center in CA. ashok.krishnaswami@kp.org. 2. Group Leader for Surgical Outcomes and Analysis for Kaiser Permanente in San Diego, CA. mary.lou.kiley@kp.org. 3. Project Manager for Surgical Outcomes and Analysis for Kaiser Permanente in San Diego, CA. faith.anthony@kp.org. 4. Senior Data Consultant for Surgical Outcomes and Analysis for Kaiser Permanente in San Diego, CA. yuexin.chen@kp.org. 5. Project Manager for Surgical Outcomes and Analysis for Kaiser Permanente in San Diego, CA. jason.x.chen@kp.org. 6. Infectious Disease Specialist at the Vacaville Medical Center in Vallejo, CA. sumanth.rajagopal@kp.org. 7. Electrophysiologist at the Santa Clara Medical Center in CA. taylor.i.liu@kp.org. 8. Electrophysiologist at the Santa Clara Medical Center in CA. charlie.young@kp.org. 9. Director of the Surgical Outcomes and Analysis Department at Kaiser Permanente in San Diego, CA. liz.w.paxton@kp.org.
Abstract
CONTEXT: There is insufficient information on the effect that advancing age and multiple chronic conditions (MCC) have on mortality after placement of an implantable cardioverter-defibrillator in patients with end-stage renal disease (ESRD) vs non-ESRD. OBJECTIVE: To assess whether a differential effect of age and MCC exists between ESRD and non-ESRD. DESIGN: Population-based, retrospective cohort study using data from the national Kaiser Permanente Cardiac Device Registry of patients who underwent placement of an implantable cardioverter-defibrillator between January 1, 2007, and December 31, 2013. MAIN OUTCOME MEASURES: All-cause mortality. RESULTS: Of 7825 patients with implantable cardioverter-defibrillator placement, ESRD-affected patients constituted 4.0% of the cohort (n = 311), were similar in age (p = 0.91), and presented with a larger comorbidity burden (3.3 ± 1.3 vs 2.4 ± 1.5, p < 0.001). The effect of advancing age (every 5 years) on mortality in the ESRD cohort (hazard ratio [HR] = 1.11, 95% confidence interval [CI] = 1.03-1.20) was less than in the non-ESRD cohort (HR = 1.28, 95% CI = 1.25-1.32). Similarly, the effect of each additional comorbidity in the ESRD cohort was less (HR = 1.04, 95% CI = 0.91-1.19) than in the non-ESRD group (HR = 1.20, 95% CI = 1.16-1.25). Lastly, ESRD was independently associated with a 3-fold greater hazard of mortality. CONCLUSIONS: Advancing age and increasing number of MCC have a differential effect on mortality risk in patients with ESRD compared with their non-ESRD counterparts. Future studies should focus on assessment of nonlinear relationships of age, MCC, and naturally occurring clusters of MCC on mortality.
CONTEXT: There is insufficient information on the effect that advancing age and multiple chronic conditions (MCC) have on mortality after placement of an implantable cardioverter-defibrillator in patients with end-stage renal disease (ESRD) vs non-ESRD. OBJECTIVE: To assess whether a differential effect of age and MCC exists between ESRD and non-ESRD. DESIGN: Population-based, retrospective cohort study using data from the national Kaiser Permanente Cardiac Device Registry of patients who underwent placement of an implantable cardioverter-defibrillator between January 1, 2007, and December 31, 2013. MAIN OUTCOME MEASURES: All-cause mortality. RESULTS: Of 7825 patients with implantable cardioverter-defibrillator placement, ESRD-affected patients constituted 4.0% of the cohort (n = 311), were similar in age (p = 0.91), and presented with a larger comorbidity burden (3.3 ± 1.3 vs 2.4 ± 1.5, p < 0.001). The effect of advancing age (every 5 years) on mortality in the ESRD cohort (hazard ratio [HR] = 1.11, 95% confidence interval [CI] = 1.03-1.20) was less than in the non-ESRD cohort (HR = 1.28, 95% CI = 1.25-1.32). Similarly, the effect of each additional comorbidity in the ESRD cohort was less (HR = 1.04, 95% CI = 0.91-1.19) than in the non-ESRD group (HR = 1.20, 95% CI = 1.16-1.25). Lastly, ESRD was independently associated with a 3-fold greater hazard of mortality. CONCLUSIONS: Advancing age and increasing number of MCC have a differential effect on mortality risk in patients with ESRD compared with their non-ESRD counterparts. Future studies should focus on assessment of nonlinear relationships of age, MCC, and naturally occurring clusters of MCC on mortality.
Authors: Andrew J Karter; Assiamira Ferrara; Jennifer Y Liu; Howard H Moffet; Lynn M Ackerson; Joe V Selby Journal: JAMA Date: 2002-05-15 Impact factor: 56.272
Authors: Mihaly K de Bie; Jaco C Lekkerkerker; Bastiaan van Dam; Andre Gaasbeek; Marjolijn van Buren; Hein Putter; Lieselot van Erven; Jeroen J Bax; Martin J Schalij; Ton J Rabelink; J Wouter Jukema Journal: Curr Med Res Opin Date: 2008-06-17 Impact factor: 2.580
Authors: Benjamin A Steinberg; Sana M Al-Khatib; Rex Edwards; JooYoon Han; Gust H Bardy; J Thomas Bigger; Alfred E Buxton; Arthur J Moss; Kerry L Lee; Richard Steinman; Paul Dorian; Alfred Hallstrom; Riccardo Cappato; Alan H Kadish; Peter J Kudenchuk; Daniel B Mark; Lurdes Y T Inoue; Gillian D Sanders Journal: JACC Heart Fail Date: 2014-10-08 Impact factor: 12.035
Authors: Mihály K de Bie; Bastiaan van Dam; André Gaasbeek; Marjolijn van Buren; Lieselot van Erven; Jeroen J Bax; Martin J Schalij; Ton J Rabelink; J Wouter Jukema Journal: Eur Heart J Date: 2009-05-22 Impact factor: 29.983